- The 8 States Most Likely to Legalize Marijuana Next
- BlackBerry Is Finally Realizing Smartphones Aren't the Answer
- Express Scripts and AbbVie Drug-Pricing Deal Might Devastate Biotech Bull Market
- Dow 18,000: Why This Market Rally May Never Happen Again
- Gilead Sciences Is Not a Buy; It's Heading Lower on Price War: Jim Cramer
Fund manager Martin Shkreli offers advice on how to avoid the next Oncothyreon blowup.
Investor Martin Shkreli believes Nektar's constipation drug is a bust and the stock is a good short.